Filings with the SEC since May 19, 2020
1,011 filings, 8 in the last 30 days
Annual report (10-K)Quarterly report (10-Q)Current report (8-K)Auditor changeCEO, CFO, COO or CAO changeRestatementLate filing noticeInsider purchaseCluster buy (3+ insiders)SEC comment letterShare offering (S-3, 424B)
All 29 events
- Nov 3, 202610-Q Quarterly report (10-Q) period ended Sep 30, 2026
- Nov 2, 20268-K Quarterly results 8-K item 2.02
- Oct 20, 20268-K Director or officer change 8-K item 5.02
- Sep 1, 2026Officer CFO change On August 27, 2026, Vertex Pharmaceuticals Incorporated (the “Company”) appointed Jonathan Poole as Executive Vice President and Chief Financial Officer of the Company, effective January 1, 2027 (the “Effective Date”).
- Aug 4, 202610-Q Quarterly report (10-Q) period ended Jun 30, 2026
- Aug 3, 20268-K Quarterly results 8-K item 2.02
- Jul 7, 20268-K Material agreement signed, Regulation FD disclosure, Other events 8-K items 1.01, 7.01, 8.01
- May 13, 20268-K Director or officer change, Shareholder vote results 8-K items 5.02, 5.07
- May 5, 202610-Q Quarterly report (10-Q) period ended Mar 31, 2026
- May 4, 20268-K Quarterly results 8-K item 2.02
- Apr 29, 20268-K Director or officer change 8-K item 5.02
- Apr 14, 2026SEC letter SEC asked 1 question about Form 10-K letters 2026-03-18 to 2026-04-14
- Mar 31, 20268-K Other events 8-K item 8.01
- Feb 13, 202610-K Annual report (10-K) period ended Dec 31, 2025
- Feb 12, 20268-K Quarterly results 8-K item 2.02
- Nov 4, 202510-Q Quarterly report (10-Q) period ended Sep 30, 2025
- Nov 3, 20258-K Quarterly results 8-K item 2.02
- Aug 5, 202510-Q Quarterly report (10-Q) period ended Jun 30, 2025
- Aug 4, 20258-K Quarterly results, Director or officer change 8-K items 2.02, 5.02
- May 19, 20258-K Other events 8-K item 8.01
- May 14, 20258-K Shareholder vote results 8-K item 5.07
- May 7, 2025SEC letter SEC asked 1 question about Form 10-K letters 2025-04-07 to 2025-05-07 · Results discussion (MD&A)
- May 6, 202510-Q Quarterly report (10-Q) period ended Mar 31, 2025
- May 5, 20258-K Quarterly results 8-K item 2.02
- Mar 28, 20258-K Other events 8-K item 8.01
- Feb 13, 2025Offering Shelf registration: shares and other securities, amount not fixed S-3ASR · Under this process, we may sell from time to time any combination of the securities described in this prospectus.
- Feb 13, 202510-K Annual report (10-K) period ended Dec 31, 2024
- Feb 10, 2025Officer CFO and COO change Wagner, Jr. as Chief Operating Officer of the Company and the appointment of Duncan J.
- Dec 20, 20248-K Regulation FD disclosure 8-K item 7.01
From the SEC filing index. Insider purchases go back 180 days (the Form 4s downloaded).
Every filing
Newest first, by kind
All 1011
Annual & quarterly 26Current reports (8-K) 55Insiders 856Proxy & votes 16Big owners (13D/13G) 27Shares & debt offered 4SEC letters 9Other 18
| Filed | Form | What it is | Period | |
|---|---|---|---|---|
| Apr 29, 2026 | DEFA14A | Extra proxy material | all files | |
| Apr 2, 2026 | DEFA14A | Extra proxy material | all files | |
| Apr 2, 2026 | DEF 14A | Proxy statement | May 13, 2026 | all files |
| Apr 3, 2025 | DEFA14A | Extra proxy material | all files | |
| Apr 3, 2025 | DEF 14A | Proxy statement | May 14, 2025 | all files |
| Apr 16, 2024 | PX14A6G | Shareholder's proxy letter | all files | |
| Apr 4, 2024 | DEFA14A | Extra proxy material | all files | |
| Apr 4, 2024 | DEF 14A | Proxy statement | May 15, 2023 | all files |
| Apr 6, 2023 | DEFA14A | Extra proxy material | all files | |
| Apr 6, 2023 | DEF 14A | Proxy statement | all files | |
| Apr 7, 2022 | DEFA14A | Extra proxy material | all files | |
| Apr 7, 2022 | DEF 14A | Proxy statement | May 18, 2022 | all files |
| Apr 29, 2021 | PX14A6G | Shareholder's proxy letter | all files | |
| Apr 8, 2021 | DEFA14A | Extra proxy material | all files | |
| Apr 8, 2021 | DEF 14A | Proxy statement | May 19, 2021 | all files |
| Jun 2, 2020 | PX14A6G | Shareholder's proxy letter | all files |
Press releases with quarterly results are attached to the 8-Ks marked "Quarterly results"; read them on Earnings releases.